ALIVUS LIFE SCIENCES LIMITED
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Healthy return on equity of 20.2%
Concerns1
- Negative free cash flow (βΉ230 Cr)
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 8 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ2.39 K Cr | β | βΉ486.00 Cr | β | β | 17.2% | 4.6% | 3.2% |
| Mar 2024 | βΉ2.28 K Cr | β | βΉ471.00 Cr | β | β | 20.2% | 5.6% | 0.9% |
| Mar 2023 | βΉ2.16 K Cr | β | βΉ467.00 Cr | β | β | 21.8% | 1.8% | 11.5% |
| Mar 2022 | βΉ2.12 K Cr | β | βΉ419.00 Cr | β | β | 20.4% | 12.6% | 19.0% |
| Mar 2021 | βΉ1.89 K Cr | β | βΉ352.00 Cr | β | β | 46.7% | 22.6% | 12.5% |
| Mar 2020 | βΉ1.54 K Cr | β | βΉ313.00 Cr | β | β | 77.9% | 73.5% | 59.7% |
| Mar 2019 | βΉ886.00 Cr | β | βΉ196.00 Cr | β | β | 222.7% | β | β |
| Mar 2018 | βΉ0.00 | β | βΉ0.00 | β | β | 0.0% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 2,481 |
| Total Expenses | 1,741 |
| EBIT / Operating Profit | 740 |
| OPM % | 30% |
| Other Income | 44 |
| Finance Costs | 4 |
| Depreciation & Amortisation | 67 |
| Profit Before Tax | 714 |
| Tax % | - |
| Net Profit / PAT | 530 |
| EPS (βΉ) | 43.27 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| ALIVUS LIFE SCIENCES LIMITEDthis co. | βΉ10.78 K Cr | βΉ2.39 K Cr | 20.30 | 3.57 | 15.17 | 4.6% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |